Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network.

(2017) J. Tonn et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving Seroreactivity-Based Detection of Glioma

(2015) Nicole Ludwig et al.   NEOPLASIA

Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma

(2011) J. A. Schwartzbaum et al.   NEURO-ONCOLOGY

O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

(2011) A. A. Brandes et al.   NEURO-ONCOLOGY

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

(2011) I. Lavon et al.   NEURO-ONCOLOGY

IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip

(2010) Christian Frezza et al.   CANCER CELL

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Marker-independent identification of glioma-initiating cells

(2010) Virginie Clément et al.   NATURE METHODS

Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas

(2010) B.-L. Liu et al.   NEURO-ONCOLOGY

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma

(2009) Myung Jin Son et al.   Cell Stem Cell

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

(2009) Amy B Heimberger et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Limits of CD133 as a marker of glioma self-renewing cells

(2009) Virginie Clément et al.   INTERNATIONAL JOURNAL OF CANCER

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome

(2009) Sophie Shnaper et al.   INTERNATIONAL JOURNAL OF CANCER

Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial

(2009) Stuart A. Grossman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging functions of microRNAs in glioblastoma

(2009) Sean Lawler et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

P16 PROMOTER METHYLATION IN THE SERUM AS A BASIS FOR THE MOLECULAR DIAGNOSIS OF GLIOMAS

(2009) Toshihiko Wakabayashi et al.   NEUROSURGERY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

(2008) A. A. Brandes et al.   CLINICAL CANCER RESEARCH

Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme

(2008) R. Pallini et al.   CLINICAL CANCER RESEARCH

Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

(2008) Anastasia Murat et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

CD133 Is a Marker of Bioenergetic Stress in Human Glioma

(2008) Corinne E. Griguer et al.   PLoS One

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE